A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 44
- Registration Number
- NCT01611363
Drug to Drug Interaction Study With Ipragliflozin and Furosemide
Phase 1
Completed
- Conditions
- Healthy SubjectsPharmacokinetics of Ipragliflozin
- Interventions
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 24
- Registration Number
- NCT01611415
Absolute Bioavailability Study With Ipragliflozin
Phase 1
Completed
- Conditions
- Bioavailability of IpragliflozinHealthy Subjects
- Interventions
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 14
- Registration Number
- NCT01611428
Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder
Phase 2
Completed
- Conditions
- Urinary Bladder, Overactive
- Interventions
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 260
- Registration Number
- NCT01604928
- Locations
- 🇧🇪
Site: 12, Brussels, Belgium
🇧🇪Site: 13, Edegem, Belgium
🇧🇪Site: 11, Gent, Belgium
A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects
Phase 1
Completed
- Conditions
- PharmacokineticsHealthy SubjectsMild and Moderate Hepatic Impairment
- Interventions
- First Posted Date
- 2012-04-18
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 32
- Registration Number
- NCT01579461
- Locations
- 🇸🇰
FNsP Bratislava, nemocnica akad. L. Dérera; Klinika pracovného lekárstva a toxikológie, Bratislava, Slovakia
A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug
Phase 3
Completed
- Conditions
- Urinary Bladder, Overactive
- Interventions
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 189
- Registration Number
- NCT01565707
- Locations
- 🇺🇸
Site: 1006, Shreveport, Louisiana, United States
🇺🇸Site: 1015, Albany, New York, United States
🇧🇪Site: 3202, Antwerp, Belgium
A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 76
- Registration Number
- NCT01565694
- Locations
- 🇺🇸
Site US1008, Tarrytown, New York, United States
🇺🇸Site US1010, Cincinnati, Ohio, United States
🇧🇪Site BE3201, Gent, Belgium
To Determine the Feasibility of a Fidaxomicin Study in Neonates and to Assess C. Difficile (Clostridium Difficile) Involvement in the Pathogenesis
Terminated
- Conditions
- Clostridium Difficile
- First Posted Date
- 2012-02-15
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 1
- Registration Number
- NCT01533844
- Locations
- 🇫🇷
Site: 3301, Poissy, Paris, France
🇫🇷Site: 3302, Lyon, France
🇩🇪Site: 4902, Erlangen, Germany
A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder
Phase 2
Completed
- Conditions
- Urologic DiseasesUrinary Bladder DiseasesSigns and SymptomsUrinary Bladder, OveractiveUrological Manifestations
- Interventions
- First Posted Date
- 2011-04-21
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 1307
- Registration Number
- NCT01340027
- Locations
- 🇧🇾
BY37101, Minsk, Belarus
🇧🇾BY37102, Minsk, Belarus
🇧🇾BY37103, Minsk, Belarus
Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms
Phase 3
Completed
- Conditions
- Benign Prostatic HyperplasiaLower Urinary Tract Symptoms
- Interventions
- First Posted Date
- 2009-11-26
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 1067
- Registration Number
- NCT01021332